WithdrawnPhase 1NCT04305678

Mepolizumab for Eosinophilic Fasciitis

Studying Eosinophilic fasciitis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mayo Clinic
Principal Investigator
Jason C Sluzevich, M.D., MD
Mayo Clinic
Intervention
Mepolizumab(drug)
Eligibility
18 years · All sexes
Timeline
2023 – 2023

Collaborators

GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04305678 on ClinicalTrials.gov

Other trials for Eosinophilic fasciitis

Additional recruiting or active studies for the same condition.

See all trials for Eosinophilic fasciitis →

← Back to all trials